Results 41 to 50 of about 1,871,454 (260)

Metastatic niche shaped by host factors influences disseminated cancer cell fate

FEBS Letters, EarlyView.
Metastasis is shaped not only by cancer cells but also by the environments they encounter. This review explores how factors such as aging, diet, the microbiome, lifestyle, and environmental exposures remodel organ‐specific niches in the lung, liver, bone, and brain, influencing where metastatic cells survive, remain dormant, or grow, and ultimately ...
Gwennan Delyth Ward, Álvaro Ruiz‐Tabas, Patricia Altea‐Manzano   +2 more
wiley   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer Patients With Different Metastatic Sites: A Systematic Review and Meta-Analysis

Frontiers in Oncology, 2020
Background: Organ-specific response patterns reported in previous studies indicate different response toward immune checkpoint inhibitors (ICIs) in non-small-cell lung cancer (NSCLC) patients with different metastatic sites.
Kaili Yang, Jiarui Li, Chunmei Bai, Zhao Sun, Lin Zhao   +4 more
doaj   +1 more source

Mutational signatures of synchronous and metachronous brain metastases from lung adenocarcinoma

Experimental Hematology & Oncology, 2023
Brain metastasis (BM) is an important cause of mortality for cancer patients. Many patients were diagnosed with brain metastases at their first visit who have not received any treatment while a subset of patients did not have distant metastases at the ...
Jianing Chen, Hainan Yang, Chao Zhao, Tao Lin, Da Liu, Weiping Hong, Changguo Shan, Cheng Zhou, Ling Bao, Caicun Zhou, Linbo Cai, Chunxia Su, Zhaoming Zhou, Lei Wen   +13 more
doaj   +1 more source

The clinical effectiveness and cost-effectiveness of ablative therapies in the management of liver metastases: systematic review and economic evaluation [PDF]

, 2014
Background: Many deaths from cancer are caused by metastatic burden. Prognosis and survival rates vary, but survival beyond 5 years of patients with untreated metastatic disease in the liver is rare.
Breen, D., George, S., Joanna Picot, Steve George, Colquitt, Jillian, Mendes, Diana, Emma Loveman, Primrose, John, Clegg, Andrew J., Picot, J., John Primrose, Cunningham, David, Andrew J Clegg, Ruters, Theo, Theo Ruers, Colquitt, J.L., Cunningham, D., Moore, E., Ruers, T., Jones, Jeremy, Jeremy Jones, Picot, Joanna, Breen, David J., Jillian L Colquitt, Primrose, J.N., Clegg, Andrew, Graeme Poston, Loveman, Emma, Emily Moore, Moore, Emily, Diana Mendes, David J Breen, Poston, G., Poston, Graeme, George, Steve, David Cunningham   +35 more
core   +1 more source

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source

Antibody-Drug Conjugates as a Potential a Systemic Treatment Strategy for Brain Metastases in Cases of Solid Tumors

Journal of Oncological Sciences
Large molecular antibody-drug conjugates (ADCs) are able to easily access the site of metastasis in the brain due to the edematous structure of brain metastases, facilitating considerably high concentrations of the cytotoxic component of these ADCs in ...
Didem DİVRİKLİOĞLU, İsmail BAYRAKÇI, Erkan ÖZCAN, İrfan ÇİÇİN   +3 more
doaj   +1 more source

Genomic landscape of the immune microenvironments of brain metastases in breast cancer

Journal of Translational Medicine, 2020
Background This study was intended to investigate the genomic landscape of the immune microenvironments of brain metastases in breast cancer. Methods Three gene expression profile datasets (GSE76714, GSE125989 and GSE43837) of breast cancer with brain ...
Wei-cheng Lu, Hui Xie, Ce Yuan, Jin-jiang Li, Zhao-yang Li, An-hua Wu   +5 more
doaj   +1 more source

Radiosurgery for Five to Fifteen Brain Metastases: A Single Centre Experience and a Review of the Literature

Frontiers in Oncology, 2022
PurposeStereotactic radiosurgery (SRS) is now mainstream for patients with 1-4 brain metastases however the management of patients with 5 or more brain metastases remains controversial.
Susanne J. Rogers, Nicoletta Lomax, Sara Alonso, Tessa Lazeroms, Oliver Riesterer   +4 more
doaj   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source